Market news

Diamond Hill Capital, a First Eagle Investment Management company, issued its Q2 2026 investor letter for its “Small Cap Strategy”. The letter can be downloaded here. The strategy returned 24.01% in the second quarter, outperforming the Russell 2000 Index’s 21.49% return. Performance was positively affected by stock selection in health care and industrials, while the Fund’s underweight position […]

Total revenue of $28.5 million, up 21% over Q2 2025

Repligen (NasdaqGS:RGEN) and BioLife Solutions recently held a merger and acquisition call. The discussion focused on potential combinations or partnerships in bioprocessing and cell and gene therapy tools. The call represents new corporate activity that is separate from routine earnings updates. Repligen enters this M&A discussion with BioLife Solutions while its shares trade at $131.06. The stock is up 9.5% over the past year, although it is down 20.3% year to date and has declined 23.6%...

RGEN's $1.5 billion BioLife acquisition aims to expand its cell therapy capabilities, adding biopreservation products and expected revenue and EPS benefits.

BioLife Solutions (BLFS) has an average rating of overweight and mean price target of $31.25, accord

BioLife Solutions (BLFS) has an average rating of overweight and mean price target of $31.13, accord

BioLife Solutions (BLFS) has an average rating of overweight and mean price target of $31.13, accord

BioLife Solutions (BLFS) has an average rating of overweight and mean price target of $31.13, accord

Repligen (NASDAQ:RGEN) said it has signed a definitive agreement to acquire BioLife Solutions in a transaction valued at approximately $1.5 billion, adding a cell therapy-focused platform that management said will expand Repligen’s exposure to one of the faster-growing areas of bioprocessing. Presi

Repligen to acquire BioLife Solutions for $1.5B to boost cell therapy bioprocessing capabilities and expand global reach.

July 22 () - Repligen Corp said on Wednesday it would buy BioLife Solutions in a cash-and-stock deal valued at ‌about $1.5 billion, to expand the drugmaking equipment provider's presence in ‌the fast-growing cell therapy market.

Fast-tracks Repligen’s leadership and customer solution offering in high-growth cell therapy market by adding BioLife’s differentiated, high-margin recurring revenue business BioLife stockholders to receive cash and Repligen common stock at a value of $31.00 per share, representing a total enterprise value of approximately $1.5 billion Compelling financially, the transaction is expected to be accretive to Repligen’s top-line growth, adjusted margins, and adjusted earnings per share by at least 5